Aims and potential for translation of our research

We study the development and function of lymphocytes with
a view to identifying the molecular pathways that control this
in health and disease.

Current research translation activities

Commercial collaborations
GlaxoSmithKline (Francesco Colucci & Elena Vigorito)
GlaxoSmithKline (Klaus Okkenhaug)
GlaxoSmithKline (Martin Turner)
Merck Serono (Francesco Colucci & Martin Turner)
Merck Serono (Klaus Okkenhaug)
Piramed Pharma (Klaus Okkenhaug)
UCB Celltech (Francesco Colucci & Klaus Okkenhaug)
UCB Celltech (Klaus Okkenhaug)

Marianne Brüggemann, a Group Leader in our Laboratory, has joined BBT Ltd on secondment to pursue translational development of new technologies for monoclonal antibody production.

Matthew Baker, co-founder and CEO of Antitope Ltd, completed his postdoctoral training in our Laboratory.

Clinical and pre-clinical collaborations
Cambridge Institute for Medical Research, University of Cambridge:
MicroRNA (Elena Vigorito & Martin Turner)
 
Department of Haematology, University of Cambridge: BclXl deamidation (Rui Zhao)
 
Dept of Hematology & Clinical Immunology, University of Perugia:
Modulation of transplantation immunity (Francesco Colucci & Klaus Okkenhaug)
 
Dept of Histology & Embryology, University of Rijeka:
Opportunistic infections (Francesco Colucci & Klaus Okkenhaug)
 
Medical Charity Funding
British Heart Foundation:
T cell infiltration in chronic heart allograft rejection (Klaus Okkenhaug)
 
• Details of previous translational activity can be found here